Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
Davey, R. T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109–15114 (1999).
Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).
Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).
Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).
Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120–125 (2019).
Cassidy, N. A. J. et al. HIV reservoir quantification using cross-subtype multiplex ddPCR. iScience 25, 103615 (2022).
Gaebler, C. et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. J. Exp. Med. 216, 2253–2264 (2019).
Delporte, M. et al. Integrative assessment of total and intact HIV-1 reservoir by a 5-region multiplexed rainbow DNA Digital PCR assay. Clin. Chem. 71, 203–214 (2025).
Reeves, D. B. et al. Impact of misclassified defective proviruses on HIV reservoir measurements. Nat. Commun. 14, 4186 (2023).
Kinloch, N. N. et al. Author Correction: HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat. Commun. 12, 2958 (2021).
Gaebler, C. et al. Sequence evaluation and comparative analysis of novel assays for intact proviral HIV-1 DNA. J. Virol. 95 https://doi.org/10.1128/JVI.01986-20 (2021).
Simonetti, F. R. et al. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proc. Natl. Acad. Sci. USA 117, 18692–18700 (2020).
Hiener, B. et al. Identification of genetically intact HIV-1 Proviruses in Specific CD4(+) T cells from effectively treated participants. Cell Rep. 21, 813–822 (2017).
Lee, G. Q. et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J. Clin. Investig. 127, 2689–2696 (2017).
Imamichi, H. et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proc. Natl. Acad. Sci. USA 113, 8783–8788 (2016).
White, J. A. et al. Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods. PLoS Pathog. 18, e1010845 (2022).
Bruner, K. M. et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat. Med. 22, 1043–1049 (2016).
Mansky, L. M. & Temin, H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087–5094 (1995).
Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G. & Hughes, S. H. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 84, 9864–9878 (2010).
Sebastian-Martin, A., Barrioluengo, V. & Menendez-Arias, L. Transcriptional inaccuracy threshold attenuates differences in RNA-dependent DNA synthesis fidelity between retroviral reverse transcriptases. Sci. Rep. 8, 627 (2018).
Hu, W. S. & Hughes, S. H. HIV-1 reverse transcription. Cold Spring Harbor Perspect. Med. 2 https://doi.org/10.1101/cshperspect.a006882 (2012).
Hwang, C. K., Svarovskaia, E. S. & Pathak, V. K. Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching. Proc. Natl. Acad. Sci. USA 98, 12209–12214 (2001).
Svarovskaia, E. S., Delviks, K. A., Hwang, C. K. & Pathak, V. K. Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching. J. Virol. 74, 7171–7178 (2000).
Roda, R. H. et al. Strand transfer occurs in retroviruses by a pause-initiated two-step mechanism. J. Biol. Chem. 277, 46900–46911 (2002).
Jetzt, A. E. et al. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol. 74, 1234–1240 (2000).
Schlub, T. E., Smyth, R. P., Grimm, A. J., Mak, J. & Davenport, M. P. Accurately measuring recombination between closely related HIV-1 genomes. PLoS Comput. Biol. 6, e1000766 (2010).
Zhuang, J. et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J. Virol. 76, 11273–11282 (2002).
Cromer, D., Grimm, A. J., Schlub, T. E., Mak, J. & Davenport, M. P. Estimating the in-vivo HIV template switching and recombination rate. AIDS 30, 185–192 (2016).
Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99–103 (2003).
Lecossier, D., Bouchonnet, F., Clavel, F. & Hance, A. J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (2003).
Zhang, H. et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94–98 (2003).
Suspene, R. et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32, 2421–2429 (2004).
Pace, C. et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80, 9259–9269 (2006).
Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).
Imamichi, H. et al. Defective HIV-1 proviruses produce viral proteins. Proc. Natl. Acad. Sci. USA 117, 3704–3710 (2020).
Singh, K. et al. Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy. AIDS 37, 2119–2130 (2023).
Scrimieri, F. et al. Transcriptionally active defective HIV-1 Proviruses and their association with immunological nonresponse to antiretroviral therapy. J. Infect. Dis. 229, 1786–1790 (2024).
Dube, M. et al. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4(+) and CD8(+) T cells. Cell Host Microbe 31, 1507–1522.e1505 (2023).
Pollack, R. A. et al. Defective HIV-1 Proviruses are expressed and can be recognized by Cytotoxic T Lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506.e494 (2017).
Lambrechts, L. et al. HIV-PULSE: a long-read sequencing assay for high-throughput near full-length HIV-1 proviral genome characterization. Nucleic Acids Res. 51, e102 (2023).
Pinzone, M. R. et al. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nat. Commun. 10, 728 (2019).
Liang, B. et al. A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1. PloS one 6, e26745 (2011).
Cho, Y. K., Jung, Y., Sung, H. & Joo, C. H. Frequent Genetic Defects in the HIV-1 5’ LTR/gag Gene in Hemophiliacs Treated with Korean Red Ginseng: Decreased Detection of Genetic Defects by Highly Active Antiretroviral Therapy. J. Ginseng Res. 35, 413–420 (2011).
Council, O. D. et al. The persistent pool of HIV-1-infected cells is formed episodically during untreated infection. J. Virol. e0097924 (2024).
Lu, C. L. et al. Relationship between intact HIV-1 proviruses in circulating CD4(+) T cells and rebound viruses emerging during treatment interruption. Proc. Natl. Acad. Sci. USA 115, E11341–E11348 (2018).
Yoshinaga, T. & Fujiwara, T. Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. J. Virol. 69, 3233–3236 (1995).
Esposito, D. & Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 17, 5832–5843 (1998).
Vink, C., Van Gent, D., Elgersma, Y. & Plasterk, R. Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J. Virol. 65, 4636–4644 (1991).
Oh, J., Chang, K. W. & Hughes, S. H. Integration of rous sarcoma virus DNA: a CA dinucleotide is not required for integration of the U3 end of viral DNA. J. Virol. 82, 11480–11483 (2008).
Joseph, K. W. et al. Deep sequencing analysis of individual HIV-1 proviruses reveals frequent asymmetric long terminal repeats. J. Virol. 96, e00122–e00122 (2022).
Pfeiffer, J. K. & Telesnitsky, A. Effects of limiting homology at the site of intermolecular recombinogenic template switching during Moloney murine leukemia virus replication. J. Virol. 75, 11263–11274 (2001).
Berkhout, B., van Wamel, J. & Klaver, B. Requirements for DNA strand transfer during reverse transcription in mutant HIV-1 virions. J. Mol. Biol. 252, 59–69 (1995).
An, W. & Telesnitsky, A. Effects of varying sequence similarity on the frequency of repeat deletion during reverse transcription of a human immunodeficiency virus type 1 vector. J. Virol. 76, 7897–7902 (2002).
Dang, Q. & Hu, W. S. Effects of homology length in the repeat region on minus-strand DNA transfer and retroviral replication. J. Virol. 75, 809–820 (2001).
Hardy, J. et al. Reverse transcription of plasma-derived HIV-1 RNA generates multiple artifacts through tRNA(Lys-3)-priming. Microbiol. Spectr. 12, e0387223 (2024).
Lanciault, C. & Champoux, J. J. Pausing during reverse transcription increases the rate of retroviral recombination. J. Virol. 80, 2483–2494 (2006).
Moumen, A. et al. Evidence for a mechanism of recombination during reverse transcription dependent on the structure of the acceptor RNA. J. Biol. Chem. 278, 15973–15982 (2003).
Watts, J. M. et al. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460, 711–716 (2009).
Piekna-Przybylska, D., Sharma, G. & Bambara, R. A. Mechanism of HIV-1 RNA dimerization in the central region of the genome and significance for viral evolution. J. Biol. Chem. 288, 24140–24150 (2013).
Shen, W., Gao, L., Balakrishnan, M. & Bambara, R. A. A recombination hot spot in HIV-1 contains guanosine runs that can form a G-quartet structure and promote strand transfer in vitro. J. Biol. Chem. 284, 33883–33893 (2009).
Harpster, C., Boyle, E., Musier-Forsyth, K. & Kankia, B. HIV-1 genomic RNA U3 region forms a stable quadruplex-hairpin structure. Biophys. Chem. 272, 106567 (2021).
Fukuda, H. et al. Cooperative methylation of human tRNA3Lys at positions A58 and U54 drives the early and late steps of HIV-1 replication. Nucleic Acids Res. 49, 11855–11867 (2021).
Wu, T., Guo, J., Bess, J., Henderson, L. E. & Levin, J. G. Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems. J. Virol. 73, 4794–4805 (1999).
Jain, V. et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208, 1202–1211 (2013).
Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88, 10056–10065 (2014).
Peluso, M. J. et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight 5 https://doi.org/10.1172/jci.insight.132997 (2020).
Gandhi, R. T. et al. Selective decay of intact HIV-1 Proviral DNA on antiretroviral therapy. J. Infect. Dis. 223, 225–233 (2021).
Anderson, E. M. et al. Dynamic shifts in the HIV proviral landscape during long term combination antiretroviral therapy: implications for persistence and control of HIV Infections. Viruses 12 https://doi.org/10.3390/v12020136 (2020).
Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe 31, 83–96.e85 (2023).
Wiegand, A. et al. Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. Proc. Natl. Acad. Sci. 114, E3659–E3668 (2017).
Kuniholm, J., Coote, C. & Henderson, A. J. Defective HIV-1 genomes and their potential impact on HIV pathogenesis. Retrovirology 19, 13 (2022).
Avettand-Fenoel, V. et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in the HAART area (ANRS CO 01). J. Med. Virol. 81, 217–223 (2009).
